The clinical utility of FDG-PET/CT in follow up and restaging of breast cancer patients

BackgroundEarly diagnosis and accurate staging of loco-regional and distant recurrence after treatment of breast cancer is decisive for further therapeutic planning. Our aim was to evaluate the role of FDG-PET/CT in the follow up and restaging of breast cancer patients.MethodsWe retrospectively evaluated 34 female patients with a history of breast cancer. Patients were referred for a PET/CT scan because of suspected recurrence (n = 15), whole body staging in already confirmed cases of recurrence (n = 5), follow up and reassurance in asymptomatic patients (n = 7), follow up after local ablative therapy of liver metastases (n = 5), follow up after treatment of bone metastases (n = 2). PET-CT findings were compared with the findings obtained by other imaging modalities, histopathology, together with clinical and imaging follow up for at least 6 months.ResultsThe PET/CT was considered pathological in 21/34 patients. Incorrect interpretations of PET/CT images occurred in 3 patients (8.8%). PET/CT showed an overall diagnostic accuracy of 91.2% with a sensitivity of 90.5% and a specificity of 92.3%. The PPV and NPV were 95% and 85.7%, respectively.ConclusionFDG-PET/CT may play a substantial role in the restaging and follow up of patients with breast cancer showing high sensitivity and specificity.